The global anesthesia and respiratory devices market size was estimated at USD 54.1 billion in 2024 and is expected to grow at a CAGR of 5.9% from 2025 to 2030. The market for anesthesia and respiratory devices is driven by an increased incidence of respiratory disorders such as Obstructive Sleep Apnea (OSA) and Chronic Obstructive Pulmonary Disease (COPD), fast urbanization, an increase in surgical operations, pollution levels, geriatric population, and smoking population. For instance, according to the Australian Institute of Health and Welfare, in 2023, COPD accounted for 50% of the total burden of disease due to respiratory conditions and 3.6% of the total disease burden. Furthermore, according to the American Lung Association, in 2022, 4.6% of adults, or 11.7 million people, reported a diagnosis of chronic bronchitis, COPD, or emphysema.
The COVID-19 pandemic significantly increased global demand for medical devices, particularly ventilators and vital sign-monitoring equipment. In response, some devices, such as anesthesia and transport ventilators, required modifications to provide long-term ventilation for critically ill patients. In addition, companies rapidly introduced new products to meet the surge in demand. For example, in April 2020, InnAccel Technologies launched a non-invasive ventilation system specifically designed for COVID-19 patients in ICUs. These factors contributed to the positive impact of the pandemic on the ventilators market.
Similarly, the capnography devices market was also significantly impacted. End‐tidal Carbon Dioxide (ETCO2) or capnography devices emerged as a valuable adjunct for assessing sedation/analgesia and ventilation in COVID-19 patients. For instance, in 2020, Medtronic reported higher demand for products such as capnography, ventilators, pulse oximetry, advanced parameter monitoring, and extracorporeal life support due to the pandemic. The company’s Respiratory, Gastrointestinal, & Renal (RGR) net sales for fiscal year 2020 reached USD 2.8 billion, a 4% increase from fiscal year 2019. This growth was partly driven by increased demand for ventilators and airway products related to COVID-19 in the fourth quarter, with notable strength in their Microstream capnography monitoring products, Puritan Bennett ventilator portfolio, and Nellcor pulse oximetry products.
The rising population of smokers is also leading to the increasing incidence of respiratory diseases, such as emphysema, bronchitis, cancer, and other lung diseases, which is leading to the growing demand for respiratory devices, hence boosting the market growth. According to WHO data published in July 2023, tobacco use is responsible for over 8 million deaths annually worldwide. Of these, more than 7 million are attributed to direct tobacco consumption, while approximately 1.3 million are due to second-hand smoke exposure among non-smokers.
Furthermore, the demand for anesthetic and respiratory equipment is expected to rise as technology continues to advance. Manufacturers are driving market growth by innovating patient care, integrating advanced patient monitors, novel metrics, IT solutions, and cutting-edge devices. For example, in September 2023, Smartmi launched the Evaporative Humidifier 3, which enhances air quality with features designed to combat dry air issues like respiratory allergies, irritation, and germ proliferation, making it ideal for individuals with respiratory conditions and homes in dry climates or with forced air heating systems.
Collaborations among market players are also contributing to the growth of anesthesia devices. In October 2022, the Hospital for Special Surgery (HSS) partnered with Lumoptik, Inc. to advance epidural technologies, pain management, and related orthopedic and neurology applications. This partnership involves a clinical evaluation of Lumoptik's BrightPoint System to improve epidural procedures. By combining HSS's expertise in anesthesia and pain management with Lumoptik's technological capabilities, the collaboration aims to enhance patient care through innovative solutions. Lumoptik's BrightPoint Epidural Needle Guidance System, a cost-effective and user-friendly device, assists clinicians in performing epidurals using the standard Loss of Resistance (LOR) technique.
The degree of innovation in the anesthesia and respiratory devices industry is high. Technological innovation in therapeutic respiratory devices includes advancements in portable ventilators, smart inhalers, and AI-driven respiratory systems. For instance, in November 2023, the U.S. startup Samay, presented clinical findings demonstrating the efficacy of its Sylvee wearable technology in accurately diagnosing COPD and forecasting critical exacerbations before onset. The company reported that its AI-supported device successfully identified "air trapping," a key early indicator of COPD exacerbations, with an accuracy of 83%. This performance was compared to traditional hospital-based Pulmonary Function Tests (PFTs), which utilize in-person spirometry, plethysmography, or CT scans.
The M&A activities, such as mergers, acquisitions, and partnerships, enable companies to expand geographically, financially, and technologically. In August 2024, ZOLL, a subsidiary of Asahi Kasei, acquired Vyaire Medical's ventilator business during Vyaire's Chapter 11 bankruptcy process. Once the acquisition is finalized, the company will integrate Vyaire's ventilators into ZOLL's product portfolio, expanding its capacity to support a wider range of clinicians and patients.
The impact of regulations is moderate to high in the industry. The industry involves several digital technologies, including AI and ML. It is regulated by different bodies in different countries. The U.S. FDA regulates anesthesia and respiratory devices, along with other medical devices in the U.S. The industry players might face severe challenges if they fail to abide by the regulations. For instance, in April 2024, a federal court mandated that Philips RS North America LLC (Philips Respironics) halt the manufacturing and distribution of most respiratory and sleep devices at three Pennsylvania facilities. This order requires the company to implement specific safety measures and ensure compliance with the Federal Food, Drug, and Cosmetic Act (FDCA).
Geographical expansion enables companies to tap into new, underserved regions with varying healthcare needs and regulatory environments. For instance, in April 2022, CAIRE, Inc. planned to expand its oxygen portfolio with companion 5 and new life intensity 10 stationary oxygen concentrators in Brazil. Due to the COVID-19 pandemic, there was shortage of oxygen across Latin America, creating an opportunity for the company to expand its oxygen therapy portfolio.
Respiratory devices accounted for a majority share of over 68.1% in the product segment in 2024. The key factors expected to fuel the segment's growth are the rising prevalence of respiratory diseases, the availability of advanced respiratory devices, the growing number of surgeries performed, and rising healthcare expenditure. These devices manage and treat conditions including fibrosis, asthma, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome. For instance, in May 2023, Drive DeVilbiss International introduced a new energy-efficient 10-liter oxygen concentrator. This device is designed to address the unique challenges of semi-urban and rural healthcare environments, making it suitable for providing oxygen therapy at primary and secondary health levels.
Anesthesia devices segment is expected to grow significantly over the forecast period, owing to the rising number of surgeries and various technological advancements by market players. For instance, in August 2020, the U.S. Food & Drug Administration (FDA) approved Getinge's Flow-c and Flow-e anesthesia systems. These additions to the Flow family of anesthesia machines utilize the same core technology. They are designed to deliver personalized anesthesia, accommodating many patient needs, including pediatric patients, neonates, and those with obesity.
The North America anesthesia and respiratory devices market accounted for the largest revenue share of 25.5% in 2024. The increasing geriatric population in the U.S. is driving a rise in surgeries, boosting market growth. According to the U.S. Census Bureau, over 54 million adults aged 65 and older were reported in the U.S. in 2021. Furthermore, the World Health Organization projects that the geriatric population will grow from 12% in 2015 to 22% by 2050.
In addition, healthcare cost containment issues and the economic crisis have compelled the government to introduce new strategies to reduce hospital stays and impose an excise tax on medical devices. These initiatives have compelled patients and physicians to opt for respiratory and anesthesia monitoring and therapeutic devices for home care. However, the excise tax is expected to negatively affect the original equipment manufacturers. The major players in the U.S. market are GE Healthcare, Koninklijke Philips N.V., Teleflex Inc., Masimo, and others.
The U.S. anesthesia and respiratory devices market accounted for the largest anesthesia and respiratory devices market share in 2024, driven by favorable reimbursement policies that support adopting these devices. A significant development occurred in March 2024, when a U.S. Congressman introduced the Supplemental Oxygen Access Reform (SOAR) Act to improve access to supplementary oxygen for Medicare beneficiaries. This legislation is expected to boost the adoption of oxygen concentrators nationwide. In addition, rising healthcare spending in the U.S. is increasing the demand for effective diagnosis and treatment of respiratory diseases, further driving the market for oxygen concentrators.
The Anesthesia and respiratory devices market in Europe is projected to experience significant growth during the forecast period. The region's robust healthcare infrastructure and commitment to innovation drive the adoption of advanced mechanical ventilators. In addition, the aging population in Europe is leading to a rise in respiratory illnesses and chronic obstructive pulmonary disease (COPD), increasing the demand for ventilatory support. For instance, Eurostat projects that by 2050, Europe will have nearly half a million centenarians, with the median age expected to rise by 4.5 years to 48.2 years.
The Anesthesia and respiratory devices market in UK had a substantial share in 2024. The growth is attributed to the active participation of market players and other organizations in developing cost-effective respiratory devices, among other factors. For instance, in February 2022, OxVent, a rapidly scalable and deployable low-cost ventilator developed by a collaboration between the University of Oxford and King’s College London, received approval for large-scale development and adoption as a social enterprise.
The Anesthesia and respiratory devices market in France is positively influenced by the increasing efforts of market players. For instance, in August 2020, ZOOOK, a French lifestyle brand, launched the Oximate Finger Tip Pulse Oximeter. This compact device is specifically designed to accurately monitor pulse rates and blood oxygen saturation levels. It features a single-button function for ease of operation and is comfortable to wear, enhancing user experience. By expanding its health-tech product range with this device, ZOOOK strengthens its market position and contributes to the overall growth of the pulse oximeter market in France.
Anesthesia and respiratory devices market in the Asia Pacific region is expected to exhibit the highest growth over the forecast period, several key factors, including rising healthcare awareness, increasing prevalence of respiratory diseases, technological advancements, and supportive government initiatives & market interventions.
The region's experience with COVID-19 significantly heightened awareness and adoption of various anesthesia and respiratory devices. For instance, in June 2021, Temasek Foundation distributed free oximeters to every Singapore household to enable regular monitoring of blood oxygen levels. This initiative aimed to address silent pneumonia, a severe complication of COVID-19 where individuals may have damaged lungs and dangerously low oxygen levels without experiencing noticeable symptoms. Oximeters are critical in alerting users to seek medical attention promptly in such cases, thus driving increased demand and adoption of pulse oximeters in the region.
Anesthesia and respiratory devices market in Japan held a significant market share in the region in 2023. Nebulizers, oxygen concentrators, ventilators, and other respiratory devices are experiencing high demand due to the rising prevalence of respiratory diseases. In Japan, hay fever, primarily triggered by cedar pollen, is the most common respiratory allergy, affecting approximately 40% of the population as of May 2023, according to Firstpost. Consequently, the market for anesthesia and respiratory devices in Japan is expected to grow as the incidence of respiratory conditions continues to rise.
Anesthesia and respiratory devices market in India is driven by the increasing initiatives. For instance, in April 2021, Koninklijke Philips N.V. announced a 7% price reduction in its oxygen concentrators in India. This move passed the benefits of custom duty reduction by the government to customers, reducing the MRP of its products. As of April 2021, the MRP of the company’s oxygen concentrator was INR 68,120 (USD 940), decreasing from INR 73,311 (USD 1,012).
The market is fragmented, competitive and is characterized by the presence of various small, medium, and large companies. The market players are involved in the deployment of strategic initiatives, such as regional expansion, product advancements, distribution partnerships, collaborations, and mergers and acquisitions to gain greater market share. For instance, in April 2022, Medtronic collaborated with GE Healthcare, aimed at focusing on unique demands and needs for care at Ambulatory Surgical Centers.
The following are the leading companies in the anesthesia and respiratory devices market. These companies collectively hold the largest market share and dictate industry trends.
View a comprehensive list of companies in the Anesthesia and Respiratory Devices Market
In May 2024, Masimo partnered with Medable Inc. to integrate medical-grade wearable devices into clinical research. Medable incorporated Masimo’s MightySat Rx pulse oximeter in its evidence-generation platform for eight large-scale pharmaceutical clinical trials. These trials, involving over 3,000 patients across 25 countries, are focused on two oncology indications: breast and lung cancer.
“Masimo’s SET pulse oximetry is sensitive enough to capture key vitals on the very ill like cancer patients, plus it works on all skin tones, all ages, and is easy to use.”
- Medable’s Vice President of Digital Outcomes and TA Strategy
In April 2024, Royal Philips, initiated the establishment of an additional R&D center within its Healthcare Innovation Center (HIC) in Maharashtra, underscoring India's increasing significance in global healthcare innovation. This new facility, set to be functional within two years, will house R&D units dedicated to Sleep & Respiratory Care, Precision Diagnosis, Image Guided Therapy, and Monitoring.
In June 2022, Medtronic and GE Healthcare obtained FDA 510(k) clearance and CE Mark approval for integrating advanced Microstream capnography technologies and INVOS regional oximetry into the CARESCAPE precision monitoring platform. This integration enhances healthcare providers' ability to monitor respiratory compromise and predict perioperative complications more effectively than traditional peripheral measurements.
Report Attribute |
Details |
Market size value in 2025 |
USD 57.0 billion |
Revenue forecast in 2030 |
USD 75.9 billion |
Growth rate |
CAGR of 5.9% from 2025 to 2030 |
Actual data |
2018 - 2024 |
Forecast period |
2025 - 2030 |
Quantitative units |
Revenue in USD million/billion, and CAGR from 2025 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Mexico; UK; Germany; Spain; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
General Electric Company; Medtronic; Teleflex Incorporated; Koninklijke Philips N.V.; Drägerwerk AG & Co. KGaA; Getinge AB.; Smiths Group plc; Fisher & Paykel Healthcare Limited; Masimo; B. Braun Melsungen AG; ResMed; Shenzhen Mindray Bio-Medical Electronics Co., Ltd; Inogen, Inc.; Caire Medical (a subsidiary of NGK Spark Plug); DeVilbiss Healthcare (a subsidiary of Drive Medical).; React Health (Respiratory Product Line from Invacare Corporation); O2 Concepts; Nidek Medical Products, Inc.; Omron Corporation; GE Healthcare; Allied Healthcare; Vectura Group Plc.; PARI Respiratory Equipment, Inc.; Aerogen; DeVilbiss Healthcare LLC; Briggs Healthcare; Beurer GmBH |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global anesthesia and respiratory devices market report based on product, and region:
Product Mode Outlook (Revenue, USD Million, 2018 - 2030)
Respiratory Devices
Respiratory Equipment
Humidifiers
Heat Humidifiers
Heated Wire Breathing Circuits
Heat Exchangers
Pass Over Humidifiers
Nebulizers
Pneumatic Nebulizers
Mesh Nebulizers
Ultrasonic Nebulizers
Oxygen Concentrator
Fixed Oxygen Concentrators
Portable Oxygen Concentrators
Positive Airway Pressure Devices
Bilevel & automatic positive airway pressure devices
Continuous positive airway pressure devices
Reusable Resuscitators
Ventilators
Adult Ventilators
Neonatal Ventilators
Respiratory Inhalers
Dry Powdered Inhalers
Metered Dose Inhaler
Respiratory Disposables
Disposable Oxygen Masks
Resuscitators
Tracheostomy Tubes
Oxygen Cannula
Respiratory Measurement Devices
Pulse Oximetry systems
Capnographs
Spirometers
Peak Flowmeters
Anesthesia Devices
Anesthesia Machines
Anesthesia Workstation
Anesthesia delivery machines
Portable
Standalone
Anesthesia Ventilators
Anesthesia Monitors
Anesthesia Disposables
Anesthesia Masks
Anesthesia Accessories
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. Some key players operating in the anesthesia and respiratory devices market include General Electric Company, Medtronic, Teleflex Incorporated, Koninklijke Philips N.V., Drägerwerk AG & Co. KGaA, Getinge AB., Smiths Group plc, Fisher & Paykel Healthcare Limited, Masimo, B. Braun Melsungen AG, ResMed, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Inogen, Inc., Caire Medical (a subsidiary of NGK Spark Plug), DeVilbiss Healthcare (a subsidiary of Drive Medical)., React Health (Respiratory Product Line from Invacare Corporation), O2 Concepts, Nidek Medical Products, Inc., Omron Corporation, GE Healthcare, Allied Healthcare, Vectura Group Plc., PARI Respiratory Equipment, Inc., Aerogen, DeVilbiss Healthcare LLC, Briggs Healthcare, and Beurer GmBH
b. Key factors that are driving the anesthesia and respiratory devices market growth include increasing demand for anesthesia and respiratory devices, an increase in the incidence of respiratory disorders, fast urbanization, an increase in surgical operations, an increase in pollution levels, a rise in the elderly population, and an increase in cigarette use.
b. The global anesthesia and respiratory devices market size was estimated at USD 54.1 billion in 2024 and is expected to reach USD 57.0 billion in 2025.
b. The global anesthesia and respiratory devices market is expected to grow at a compound annual growth rate of 5.9% from 2025 to 2030 to reach USD 75.9 billion by 2030.
b. North America dominated the anesthesia and respiratory devices market with a share of 25.5% in 2024. This is attributable to the increasing geriatric population, high investments by pharmaceutical companies, and rising healthcare expenditure.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."